KR20260007630A - 생물 활성이 저하된 항체 배리언트 - Google Patents

생물 활성이 저하된 항체 배리언트

Info

Publication number
KR20260007630A
KR20260007630A KR1020257042067A KR20257042067A KR20260007630A KR 20260007630 A KR20260007630 A KR 20260007630A KR 1020257042067 A KR1020257042067 A KR 1020257042067A KR 20257042067 A KR20257042067 A KR 20257042067A KR 20260007630 A KR20260007630 A KR 20260007630A
Authority
KR
South Korea
Prior art keywords
nemolizumab
antibody
variant
peptide
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257042067A
Other languages
English (en)
Korean (ko)
Inventor
겐사쿠 호소구치
아이 하라
소타 마스다
미사토 다카기
슈스케 남부
구미 사토
Original Assignee
추가이 세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 추가이 세이야쿠 가부시키가이샤 filed Critical 추가이 세이야쿠 가부시키가이샤
Publication of KR20260007630A publication Critical patent/KR20260007630A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020257042067A 2021-12-22 2022-12-21 생물 활성이 저하된 항체 배리언트 Pending KR20260007630A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JPJP-P-2021-207714 2021-12-22
JP2021207714 2021-12-22
KR1020237004346A KR102902883B1 (ko) 2021-12-22 2022-12-21 생물 활성이 저하된 항체 배리언트
PCT/JP2022/047035 WO2023120561A1 (ja) 2021-12-22 2022-12-21 生物活性が低下した抗体バリアント

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020237004346A Division KR102902883B1 (ko) 2021-12-22 2022-12-21 생물 활성이 저하된 항체 배리언트

Publications (1)

Publication Number Publication Date
KR20260007630A true KR20260007630A (ko) 2026-01-14

Family

ID=86902603

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257042067A Pending KR20260007630A (ko) 2021-12-22 2022-12-21 생물 활성이 저하된 항체 배리언트
KR1020237004346A Active KR102902883B1 (ko) 2021-12-22 2022-12-21 생물 활성이 저하된 항체 배리언트

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237004346A Active KR102902883B1 (ko) 2021-12-22 2022-12-21 생물 활성이 저하된 항체 배리언트

Country Status (7)

Country Link
US (1) US20250163163A1 (cg-RX-API-DMAC7.html)
EP (1) EP4455163A4 (cg-RX-API-DMAC7.html)
JP (3) JP7721630B2 (cg-RX-API-DMAC7.html)
KR (2) KR20260007630A (cg-RX-API-DMAC7.html)
CN (1) CN118613503A (cg-RX-API-DMAC7.html)
TW (1) TW202340249A (cg-RX-API-DMAC7.html)
WO (1) WO2023120561A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3284480T3 (fi) 2015-04-14 2025-09-11 Chugai Pharmaceutical Co Ltd IL-31-antagonistia vaikuttavana ainesosana sisältävä farmaseuttinen koostumus atooppisen ihottuman ehkäisemiseksi ja/tai hoitamiseksi
WO2021100794A1 (ja) 2019-11-20 2021-05-27 中外製薬株式会社 抗体含有製剤

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007142325A1 (ja) 2006-06-08 2007-12-13 Chugai Seiyaku Kabushiki Kaisha 炎症性疾患の予防または治療剤
WO2009072604A1 (ja) 2007-12-05 2009-06-11 Chugai Seiyaku Kabushiki Kaisha 抗nr10抗体、およびその利用
WO2010064697A1 (ja) 2008-12-05 2010-06-10 中外製薬株式会社 抗nr10抗体、およびその利用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2418220T (pt) * 2003-12-10 2017-10-04 Squibb & Sons Llc Anticorpos contra interferão alfa e suas utilizações
KR20260090008A (ko) * 2017-11-01 2026-06-16 추가이 세이야쿠 가부시키가이샤 생물 활성이 저하된 항체 배리언트 및 아이소폼
SG11202009629YA (en) * 2018-04-02 2020-10-29 Amgen Inc Erenumab compositions and uses thereof
WO2021100794A1 (ja) 2019-11-20 2021-05-27 中外製薬株式会社 抗体含有製剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007142325A1 (ja) 2006-06-08 2007-12-13 Chugai Seiyaku Kabushiki Kaisha 炎症性疾患の予防または治療剤
WO2009072604A1 (ja) 2007-12-05 2009-06-11 Chugai Seiyaku Kabushiki Kaisha 抗nr10抗体、およびその利用
WO2010064697A1 (ja) 2008-12-05 2010-06-10 中外製薬株式会社 抗nr10抗体、およびその利用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
N Engl J Med 2020; 383:141-150

Also Published As

Publication number Publication date
JPWO2023120561A1 (cg-RX-API-DMAC7.html) 2023-06-29
WO2023120561A1 (ja) 2023-06-29
KR102902883B1 (ko) 2025-12-22
US20250163163A1 (en) 2025-05-22
EP4455163A1 (en) 2024-10-30
JP7721630B2 (ja) 2025-08-12
JP2023159309A (ja) 2023-10-31
TW202340249A (zh) 2023-10-16
KR20240117039A (ko) 2024-07-31
CN118613503A (zh) 2024-09-06
JP2026063423A (ja) 2026-04-10
JP7812826B2 (ja) 2026-02-10
EP4455163A4 (en) 2025-12-24

Similar Documents

Publication Publication Date Title
JP7716441B2 (ja) 獣医用抗il-31抗体
US20260092111A1 (en) Trem2 antibodies and uses thereof
AU2018241141B2 (en) Pertuzumab variants and evaluation thereof
EP3819313A1 (en) Bispecific antibody and use thereof
RS63513B1 (sr) Anti-transtiretin antitela
RS63906B1 (sr) Anti-transtiretin antitela
US12110330B2 (en) Compositions of programmed death receptor 1 (PD-1) antibodies and methods of obtaining the compositions thereof
JP2026063423A (ja) 生物活性が低下した抗体バリアント
TW201636372A (zh) 抗甲狀腺素運送蛋白抗體
WO2021216810A1 (en) Long-acting anti-il31 antibodies for veterinary use
US20260035465A1 (en) Pharmaceutical compositions of programmed death receptor 1 (pd-1) antibodies and ph20 variants or fragments thereof
US20260034211A1 (en) PHARMACEUTICAL COMPOSITIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND rHuPH20 OR VARIANTS OR FRAGMENTS THEREOF
JP7097433B2 (ja) 宿主細胞ガレクチンおよび他の夾雑物からグリコシル化タンパク質を精製する方法
CN117203233A (zh) 抗tslp抗体组合物及其用途
CN121930345A (zh) 抗-pd-1抗体
JP2019508380A (ja) Egfrに対するグリコシル化キメラ抗体での癌の処置のための改善された安全性
HK40108969A (en) Antibody variant with reduced biological activity
CN111234021A (zh) 一种抗ccr5抗体及其在治疗肿瘤中的应用

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)